The complexity of cancer chemotherapy requires pharmacists be familiar with the complicated regimens and highly toxic agents used. This column reviews various issues related to preparation, dispensing, and administration of antineoplastic therapy, and the agents, both commercially available and investigational, used to treat malignant diseases.
Get full access to this article
View all access options for this article.
References
1.
de BonoJ.S., OudardS., OzgurogluM.Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: A randomized open-label trial. Lancet.2010; 376(9747): 1147–1154.
2.
HeidenreichA., ScholzH.J., RogenhoferS.Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: Results from the German compassionate-use programme. Eur Urol.2013; 63(6): 977–982.
3.
HeidenreichA., BracardaS., MasonM.Safety of cabazitaxel in senior adults with metastatic castration-resistant prostate cancer: Results of the European compassionate-use programme. Eur J Cancer.2014; 50(6): 1090–1099.
4.
CalvoO.F., ParraE.F., Perez-ValderramaB.Weekly cabazitaxel in “unfit” metastatic castration-resistant prostate cancer patients (mCRPC) progressing after docetaxel (D) treatment: Preliminary results of CABASEM-SOGUG phase II trial. J Clin Oncol.2015; 33(Suppl 7): abstr 167.
5.
Clement-ZhaoA., AuvrayM., VerretB., VanoY.A., AngelerguesA., OudardS.Safety and efficacy of 2-weekly cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol.2015; 33(Suppl 7): abstr 284.
BaschE., PrestrudA.A., HeskethP.J.Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol.2011; 29(31): 4189–4198.
CoorsE.A., SeyboldH., MerkH.F., MahlerV.Polysorbate 80 in medical products and nonimmunologic anaphylactoid reactions. Ann Allergy Asthma Immunol.2005; 95(6): 593–599.
13.
NorrisL.B., QureshiZ.P., BookstaverP.B.Polysorbate 80 hypersensitivity reactions: A renewed call to action. Commun Oncol.2010; 7(9): 425–428.
14.
FerronG.M., DaiY., SemiondD.Population pharmacokinetics of cabazitaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol.2013; 71(3): 681–692.
